Literature DB >> 12468556

Treatment of cardiovascular and renal risk factors in the diabetic hypertensive.

James R Sowers1, Steven Haffner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468556     DOI: 10.1161/01.hyp.0000042097.39655.b7

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  16 in total

Review 1.  Pathogenesis of hypertension in diabetes.

Authors:  Sameer N Stas; Fadi A El-Atat; James R Sowers
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  Blood pressure control in diabetes-the Indian perspective.

Authors:  Vijay Viswanathan; T P Smina
Journal:  J Hum Hypertens       Date:  2019-05-17       Impact factor: 3.012

Review 3.  Management of diabetic and hypertensive cardiovascular disease.

Authors:  Edward D Frohlich; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 4.  Antihypertensive properties of plant-based prebiotics.

Authors:  Siok-Koon Yeo; Lay-Gaik Ooi; Ting-Jin Lim; Min-Tze Liong
Journal:  Int J Mol Sci       Date:  2009-08-10       Impact factor: 6.208

Review 5.  Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management.

Authors:  Fadi El-Atat; Samy I McFarlane; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 6.  Stroke in patients with diabetes and hypertension.

Authors:  Samy I McFarlane; Domenic A Sica; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-05       Impact factor: 3.738

7.  Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.

Authors:  Dion H Zappe; James R Sowers; Willa A Hsueh; Steven M Haffner; Prakash C Deedwania; Vivian A Fonseca; Lucy Keeling; Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-12       Impact factor: 3.738

8.  Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.

Authors:  Henry R Black; George L Bakris; Michael A Weber; Robert Weiss; Mahfouz El Shahawy; Richard Marple; Georges Tannoury; Stuart Linas; Brian L Wiens; Jennifer V Linseman; Robert Roden; Michael J Gerber
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738

Review 9.  Hypertension and the cardiometabolic syndrome.

Authors:  Camila Manrique; Guido Lastra; Adam Whaley-Connell; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

10.  Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.

Authors:  James R Sowers; Joel M Neutel; Elijah Saunders; George L Bakris; William C Cushman; Keith C Ferdinand; Elizabeth O Ofili; Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.